^
Association details:
| Biomarker: | EML4-ALK I1171N + EML4-ALK L1196M |
|---|---|
| Cancer: | Malignant Pleural Mesothelioma |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report
Published date:
05/26/2020
Excerpt:
In this case report, we describe a patient with EML4-ALK-rearranged stage IIIB MPM who was administered with alectinib and lorlatinib as first-line and fourth-line therapy, respectively....Sequencing analysis revealed the emergence of ALK I1171N and L1196M at alectinib progression.
DOI:
10.1177/1753466620935770
